Wednesday, 18 November 2026LatestVideosAboutContact
Latest
In a year of AI, why ‘human’ is Cambridge Dictionary’s word of 2026Karnataka Bank appoints Udaya Kumar Hebbar as MD and CEOMicrosoft, Apple, NSA Outages Within A Week: Is America's Digital Infra Really That Fragile? Here's What HappenedIND vs NZ 1st Test: Wellington Pitch Report, Weather Forecast & Rain PredictionDelhi Pollution: GRAP-3 Lifted In Delhi-NCR, Which Restrictions Have Been Removed?HDFC Bank slips; stock options granted at Tuesday’s close priceMicrosoft takes on OpenAI and Anthropic with cheaper AI models, flexible licensingBengaluru Horror: Scrap Dealer Tied Up, Set On Fire; Fellow Rag Pickers SuspectedFC Goa confirms Bambolim as new home for second half of ISL 2026-27India complains to AFC over racist gesture by Palestine playerNepal gets nod to import 350 MW of power from India during winterBJP slams Rahul Gandhi over remarks at Columbia University
HealthUpdated 20 min ago

What Is MOGENRY? Experimental Gene Therapy Brings New Hope For People With Vision Loss

Image: ABP Live
A new gene therapy is raising hopes for people living with Retinitis Pigmentosa, a rare genetic eye disorder that gradually damages the retina and can lead to severe vision loss or blindness. Known as MOGENRY, the experimental treatment aims to help patients regain some visual function, even after the light-sensitive cells in their retina have been damaged.

Developed by US-based biotechnology company Nanoscope Therapeutics, MOGENRY uses an innovative approach called optogenetic gene therapy. The treatment is designed to make surviving retinal cells sensitive to light, potentially allowing patients with advanced retinal degeneration to regain some ability to see.

What Is MOGENRY Gene Therapy?

MOGENRY is an optogenetic gene therapy developed for people suffering from Retinitis Pigmentosa (RP). The condition causes the gradual deterioration of photoreceptors, the specialised cells in the retina responsible for detecting light and helping the brain process visual information.

Unlike conventional gene therapies that generally aim to correct or replace faulty genes responsible for a disease, MOGENRY follows a different approach. It attempts to make other surviving cells in the retina responsive to light, helping them take over some of the functions of damaged photoreceptors.

This approach could be particularly significant for patients whose photoreceptor cells have already deteriorated due to the progressive condition.

ALSO READ | AIIMS Doctors Treat Rare Cancer Relapse After 10 Years; Here Are The Causes And Warning Signs

How Does MOGENRY Therapy Work?

The therapy uses a specially designed light-sensitive gene that is delivered into the eye with the help of a viral vector. The vector acts as a carrier, transporting the genetic material to surviving cells in the retina.

Once the gene reaches these cells, it aims to make them responsive to light. These modified retinal cells can then help convert light into electrical signals, which are transmitted to the brain through the visual pathway.

Normally, photoreceptors perform this function. However, in people with Retinitis Pigmentosa, these cells gradually become damaged and lose their ability to detect light.

By making surviving retinal cells light-sensitive, MOGENRY aims to bypass the damaged photoreceptors and restore some visual function. The treatment is administered through an injection into the eye.

Why Could MOGENRY Be Important For Patients In India?

The development of this therapy could be particularly relevant for India, where Retinitis Pigmentosa affects a significant number of people.

According to estimates cited in the report, the condition affects approximately one in every 4,000 people worldwide. In India, the estimated prevalence is around one in every 1,000 people, suggesting that more than 10 lakh people in the country could be living with the disorder.

If MOGENRY receives the necessary regulatory approvals and proves effective in further testing, it could potentially offer a new treatment option to Indian patients.

Another important aspect of the therapy is that it does not depend on correcting one specific faulty gene. This could make the approach relevant to patients whose Retinitis Pigmentosa is caused by different genetic mutations.

ALSO READ | Doc Talk | Abdominal Epilepsy: Unusual Seizure Symptoms That May Feel Like Digestive Problems

Can MOGENRY Restore Vision Completely?

MOGENRY is being studied as a potential treatment for people who have experienced significant vision loss due to Retinitis Pigmentosa. Its approach focuses on enabling surviving retinal cells to respond to light rather than repairing the damaged photoreceptors themselves.

However, it is important to understand that the therapy is not an established cure for blindness. Its effectiveness, long-term benefits and suitability for different patients will need to be assessed through further clinical evaluation and regulatory review.

For now, the development represents a promising direction in research into genetic eye disorders and could open new possibilities for people affected by progressive vision loss.

 [Disclaimer: The information provided in the article is intended for general informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition.]

This content is published by ABP Live - Health and has not been created or edited by Hello Headlines. View original

More in Health

See all